What’s the deal with Alzheimer’s disease and amyloid?

A hypothesis on shaky ground

At the end of last month, Neurobiology of Aging retracted a 2011 paper linking a form of amyloid-β to memory loss in Alzheimer’s. It has been reported that this is not an isolated incident: multiple studies that placed amyloid at the center of the disease have been pulled, and it has been reported that some researchers have even been indicted for fraud. The kicker? Decades and billions of dollars later, most therapies aimed at amyloid have failed to deliver meaningful clinical benefit. Ouch.

How we got here

The story goes back more than a century. Alois Alzheimer first described plaques and tangles in 1906. Amyloid-β entered the scene in 1984, and the link looked promising: the APP gene sits on chromosome 21, which helps explain why people with Down syndrome—who have an extra copy of that chromosome—often develop dementia. Add in familial APP mutations discovered in the 1980s and a 2006 Nature paper tying a specific extracellular form of amyloid-β to memory loss, and you have a tidy target. Neat, neat, neat. Too neat, perhaps.

Mice, vaccines, and misplaced confidence

Transgenic mice carrying human APP mutations cleared plaques when treated with anti-amyloid vaccines and antibodies — a result that launched entire drug development programs. But mice don’t naturally get Alzheimer’s. Translating those results to humans has been a recurring dead end. PET scans and blood biomarkers finally let clinicians see amyloid in living patients, but clearing plaques hasn’t translated into restored cognition. The emotional toll is real: patients and families pinned hope on a target that now looks like a cul‑de‑sac.

What happens next?

So what now? The field faces a reckoning — not just about amyloid, but about model systems, replication, and how drug development bets are placed. Some researchers call for broader exploration of inflammation, vascular contributions, tau, and metabolic factors. Others demand tougher standards and more transparency. Can Alzheimer’s research course-correct before more time and trust are wasted? That’s the question scientists — and millions of patients — desperately want answered.

Sources: arstechnica